Improved Antitumor Activity of the Fluoropyrimidine Polymer CF10 in Preclinical Colorectal Cancer Models through Distinct Mechanistic and Pharmacologic Properties
Open Access
- 23 December 2020
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 20 (3) , 553-563
Abstract
Chemotherapy regimens that include 5-fluorouracil (5-FU) are central to colorectal cancer treatment; however, risk/benefit concerns limit 5-FU’s use, necessitating development of improved fluoropyrimidine (FP) drugs. In our study, we evaluated a second-generation nanoscale FP polymer, CF10, for improved antitumor activity. CF10 was more potent than the prototype FP polymer F10 and much more potent than 5-FU in multiple colorectal cancer cell lines including HCT-116, LS174T, SW480, and T84D. CF10 displayed improved stability to exonuclease degradation relative to F10 and reduced susceptibility to thymidine antagonism due to extension of the polymer with arabinosyl cytidine. In colorectal cancer cells, CF10 strongly inhibited thymidylate synthase (TS), induced Top1 cleavage complex formation and caused replication stress, while similar concentrations of 5-FU were ineffective. CF10 was well tolerated in vivo and invoked a reduced inflammatory response relative to 5-FU. Blood chemistry parameters in CF10-treated mice were within normal limits. In vivo, CF10 displayed antitumor activity in several colorectal cancer flank tumor models including HCT-116, HT-29, and CT-26. CF10’s antitumor activity was associated with increased plasma levels of FP deoxynucleotide metabolites relative to 5-FU. CF10 significantly reduced tumor growth and improved survival (84.5 days vs. 32 days; P < 0.0001) relative to 5-FU in an orthotopic HCT-116-luc colorectal cancer model that spontaneously metastasized to liver. Improved survival in the orthotopic model correlated with localization of a fluorescent CF10 conjugate to tumor. Together, our preclinical data support an early-phase clinical trial of CF10 for treatment of colorectal cancer.Keywords
All Related Versions
Funding Information
- HHS | NIH | National Cancer Institute (R21 CA218933)
- HHS | NIH | National Cancer Institute (P30 CA012197)
- HHS | NIH | National Cancer Institute (R01 CA212600)
- HHS | NIH | National Cancer Institute (P30 CA056036)
- HHS | NIH | National Cancer Institute (R01 CA219187)
This publication has 43 references indexed in Scilit:
- TDP1 repairs nuclear and mitochondrial DNA damage induced by chain-terminating anticancer and antiviral nucleoside analogsNucleic Acids Research, 2013
- A rapid and sensitive assay for DNA–protein covalent complexes in living cellsNucleic Acids Research, 2013
- Unique dual targeting of thymidylate synthase and topoisomerase1 by FdUMP[10] results in high efficacy against AML and low toxicityBlood, 2012
- Orthotopic Mouse Model of Colorectal CancerJournal of Visualized Experiments, 2007
- 5-Fluorouracil Incorporated into DNA Is Excised by the Smug1 DNA Glycosylase to Reduce Drug CytotoxicityCancer Research, 2007
- Efficacy of sequential treatment of HCT116 colon cancer monolayers and xenografts with docetaxel, flavopiridol, and 5-fluorouracilActa Pharmacologica Sinica, 2006
- Pyrimidine pathways in health and diseaseTrends in Molecular Medicine, 2005
- 5-Fluorouracil incorporation into RNA and DNA in relation to thymidylate synthase inhibition of human colorectal cancersAnnals of Oncology, 2004
- Enhanced DNA‐Directed Effects of FdUMP[10] Compared to 5FUNucleosides, Nucleotides & Nucleic Acids, 2004
- Display and Analysis of Patterns of Differential Activity of Drugs Against Human Tumor Cell Lines: Development of Mean Graph and COMPARE AlgorithmJNCI: Journal of the National Cancer Institute, 1989